CinCor Pharma, Inc.
CinCor Pharma, Inc. (CINC) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · CINC · as of Jun 9, 2026
Activity summary
Buy transactions
6
P-Purchase only
Sell transactions
2
12 Months
Buy/Sell ratio
3.00
Buy/Sell (by trades)
Overall sentiment
CinCor Pharma, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
CINC insider buying and selling by quarter
CINC insider selling · CINC insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Recent insider transactions
CINC executive sell shares · CINC board member insider trading · CINC insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Feb 24, 2023 | 5AM Partners VI, LLC 10 percent owner | Other | 496,323 | $12.90M⚡ | Form 4 |
| Feb 24, 2023 | HEALY JAMES Director | Other | 9,803 | $255K | Form 4 |
| Feb 24, 2023 | HEALY JAMES Director | Other | 19,608 | — | Form 4 |
| Nov 28, 2022 | HEALY JAMES Director | Sale | 6,000 | $86K | Form 4 |
| Feb 24, 2023 | HEALY JAMES Director | Other | 6,073,949 | $157.92M⚡ | Form 4 |
| Feb 24, 2023 | Freeman Mason Chief Medical Officer | Other | 2,494 | $65K | Form 4 |
| Jun 10, 2022 | Freeman Mason Chief Medical Officer | Sale | 6 | $91 | Form 4 |
| Feb 24, 2023 | Freeman Mason Chief Medical Officer | Other | 100 | $3K | Form 4 |
| Feb 24, 2023 | Freeman Mason Chief Medical Officer | Other | 40,000 | — | Form 4 |
| Feb 24, 2023 | Kalb Michael Wayne EVP & Chief Financial Officer | Other | 202,437 | $5.26M⚡ | Form 4 |
| Feb 24, 2023 | Pearce Catherine COO | Other | 140,149 | $3.64M⚡ | Form 4 |
| Feb 24, 2023 | Pearce Catherine COO | Other | 1,500 | $39K | Form 4 |
| Feb 24, 2023 | Pearce Catherine COO | Other | 15,000 | — | Form 4 |
| Feb 24, 2023 | de Garidel Marc CEO · Director | Other | 12,500 | $325K | Form 4 |
| Feb 24, 2023 | de Garidel Marc CEO · Director | Other | 200,000 | — | Form 4 |
| Jan 26, 2023 | de Garidel Marc CEO · Director | Award | 200,000 | — | Form 4 |
| Jan 26, 2023 | Pearce Catherine COO | Award | 15,000 | — | Form 4 |
| Jan 26, 2023 | Kalb Michael Wayne EVP & Chief Financial Officer | Award | 177,000 | — | Form 4 |
| Jan 26, 2023 | Freeman Mason Chief Medical Officer | Award | 40,000 | — | Form 4 |
| Jan 11, 2023 | Pearce Catherine COO | Option | 13,235 | — | Form 4 |
| Jan 11, 2023 | Pearce Catherine COO | Other | 3,997 | $115K | Form 4 |
| Nov 4, 2022 | Kalb Michael Wayne EVP & Chief Financial Officer | Award | 25,437 | — | Form 4 |
| Aug 15, 2022 | 5AM Partners VI, LLC 10 percent owner | Purchase | 112,667 | $3.38M⚡ | Form 4 |
| Aug 15, 2022 | 5AM Partners VI, LLC 10 percent owner | Purchase | 487,333 | $14.62M⚡ | Form 4 |
| Aug 15, 2022 | 5AM Opportunities II, L.P. Director | Purchase | 487,333 | $14.62M⚡ | Form 4 |
5AM Partners VI, LLC
10 percent owner
Date
Feb 24
Shares
496,323
Price
$26.00
Value
$12.90M ⚡
Freeman Mason
Chief Medical Officer
Date
Feb 24
Shares
2,494
Price
$26.00
Value
$65K
Kalb Michael Wayne
EVP & Chief Financial Officer
Date
Feb 24
Shares
202,437
Price
$26.00
Value
$5.26M ⚡
Kalb Michael Wayne
EVP & Chief Financial Officer
Date
Jan 26
Shares
177,000
Price
—
Value
—
Kalb Michael Wayne
EVP & Chief Financial Officer
Date
Nov 4
Shares
25,437
Price
—
Value
—
5AM Partners VI, LLC
10 percent owner
Date
Aug 15
Shares
112,667
Price
$30.00
Value
$3.38M ⚡
5AM Partners VI, LLC
10 percent owner
Date
Aug 15
Shares
487,333
Price
$30.00
Value
$14.62M ⚡
5AM Opportunities II, L.P.
Director
Date
Aug 15
Shares
487,333
Price
$30.00
Value
$14.62M ⚡
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About CINC insider trading
CINC insider trades
CinCor Pharma, Inc. (CINC) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including CINC. Over the past 12 months, 0 insiders have filed transactions with the SEC. CINC insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For CinCor Pharma, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
CINC insider trading · 5 questionsThe insiders of CinCor Pharma, Inc. (CINC) include executives and directors such as CINC, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026